Related Experiment Video
Updated: Feb 10, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate
Harrie J M Gijsen1, Sergio A Alonso de Diego2, Michel De Cleyn1
1Neuroscience Medicinal Chemistry, Janssen Research & Development , Janssen Pharmaceutica NV , Turnhoutseweg 30 , B-2340 Beerse , Belgium.
Abstract:
In previous studies, the introduction of electron withdrawing groups to 1,4-oxazine BACE1 inhibitors reduced the p Ka of the amidine group, resulting in compound 2 that showed excellent in vivo efficacy, lowering Aβ levels in brain and CSF. However, a suboptimal cardiovascular safety margin, based on QTc prolongation, prevented further progression. Further optimization resulted in the replacement of the 2-fluoro substituent by a CF3-group, which reduced hERG inhibition. This has led to compound 3, with an improved cardiovascular safety margin and sufficiently safe in GLP toxicity studies to progress into clinical trials.
Related Concept Videos
Antihypertensive Drugs: Action of β1 Blockers
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Benzene to 1,4-Cyclohexadiene: Birch Reduction Mechanism
Optimal Foraging
Electrophilic 1,2- and 1,4-Addition of X2 to 1,3-Butadiene
Electrophilic 1,2- and 1,4-Addition of HX to 1,3-Butadiene

